{
  "thread": {
    "uuid": "b2bacf2abae36f9208247886bbb82ad839213ebe",
    "url": "http://yuanchuang.10jqka.com.cn/20250731/c670037929.shtml",
    "site_full": "yuanchuang.10jqka.com.cn",
    "site": "10jqka.com.cn",
    "site_section": "http://yuanchuang.10jqka.com.cn/mrnxgg_list/",
    "site_categories": [],
    "section_title": "异动股揭秘_原创_同花顺财经",
    "site_title": null,
    "title": "涨停雷达：创新药+药品注册+化学制剂 昂利康触及涨停",
    "title_full": "涨停雷达：创新药+药品注册+化学制剂 昂利康触及涨停",
    "published": "2025-07-31T06:41:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 7186,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "b2bacf2abae36f9208247886bbb82ad839213ebe",
  "url": "http://yuanchuang.10jqka.com.cn/20250731/c670037929.shtml",
  "ord_in_thread": 0,
  "author": "同花顺金融研究中心",
  "published": "2025-07-31T06:41:00.000+03:00",
  "title": "涨停雷达：创新药+药品注册+化学制剂 昂利康触及涨停",
  "text": "今日走势： 昂利康 （ 002940 ）今日触及涨停板，该股近一年涨停14次。\n　　异动原因揭秘：1、据2025年7月30日公告，昂利康获得美索巴莫注射液药品注册证书，该药品用于急性骨骼肌疼痛治疗，视同通过一致性评价，将进一步丰富公司产品管线。\n2、据2025年7月18日互动易，公司逐步实现由传统仿制药向特色仿制药、改良型新药和创新药相结合的“仿创协同”战略转型，创新药项目ALK-N001于2025年4月获药物临床试验批准通知书，目前处于I期临床阶段。\n3、据2024年年报，昂利康主要从事化学原料药、化学制剂、药用辅料及特色中间体系列产品的研发、生产和销售，覆盖抗感染、心血管、肾病、麻醉疼痛等多个领域。\n（免责声明：本内容由AI技术搜集公开信息总结生成，仅供参考，不构成投资建议，以上市公司公告为准）\n　　后市分析：该股今日触及涨停，后市或有继续冲高动能。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Economy, Business and Finance",
    "Science and Technology"
  ],
  "topics": [
    "Economy, Business and Finance->products and services",
    "Economy, Business and Finance->chemicals",
    "Economy, Business and Finance->healthcare industry",
    "Science and Technology->technology and engineering",
    "Science and Technology->biomedical science",
    "Science and Technology->scientific publication"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-07-31T07:50:03.644+03:00",
  "updated": "2025-07-31T07:56:27.000+03:00"
}